<code id='4255DF733C'></code><style id='4255DF733C'></style>
    • <acronym id='4255DF733C'></acronym>
      <center id='4255DF733C'><center id='4255DF733C'><tfoot id='4255DF733C'></tfoot></center><abbr id='4255DF733C'><dir id='4255DF733C'><tfoot id='4255DF733C'></tfoot><noframes id='4255DF733C'>

    • <optgroup id='4255DF733C'><strike id='4255DF733C'><sup id='4255DF733C'></sup></strike><code id='4255DF733C'></code></optgroup>
        1. <b id='4255DF733C'><label id='4255DF733C'><select id='4255DF733C'><dt id='4255DF733C'><span id='4255DF733C'></span></dt></select></label></b><u id='4255DF733C'></u>
          <i id='4255DF733C'><strike id='4255DF733C'><tt id='4255DF733C'><pre id='4255DF733C'></pre></tt></strike></i>

          leisure time

          leisure time

          author:entertainment    Page View:366
          A medical insurance document printed with the words "COPAY," "DEDUCTIBLE," "COINSURANCE," "NON-COVERED," next to a pen — coverage from STAT
          Adobe

          WASHINGTON — Insurers will have to count drug copay coupons toward deductibles and patient spending caps in most cases, after a Biden move in federal court on Tuesday.

          Drug companies use copay coupons to help patients cover the cost of their drugs.

          advertisement

          Before now, when drug companies helped patients pay their share of drug costs, insurers often didn’t count that assistance toward deductibles and out-of-pocket limits. In insurance jargon, this tactic is called a copay accumulator. Previously, the practice was only allowed when drug companies give coinsurance assistance for brand drugs with generic competition. The Trump administration let insurers use the tactic when cheaper generics were not available.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          Medical leaders decry Supreme Court decision on affirmative action
          Medical leaders decry Supreme Court decision on affirmative action

          STEFANIREYNOLDS/AFPviaGettyImagesMedicalleadersonThursdayreactedswiftlytotheSupremeCourt’sdecisionto

          read more
          PBMs drew scrutiny in House hearing — and so did pharma
          PBMs drew scrutiny in House hearing — and so did pharma

          Rep.JamesComer,chairoftheHouseOversightCommitteeKevinDietsch/GettyImagesWASHINGTON—Congresswantstore

          read more
          FDA approval of Sarepta Duchenne genetic therapy gives me hope
          FDA approval of Sarepta Duchenne genetic therapy gives me hope

          Duchennemusculardystrophyhistopathology.Dr.EdwinP.Ewing,Jr./CDCWhenIwasdiagnosedwithDuchennemuscular

          read more

          Private equity could exacerbate cardiology's overuse problem, experts fear

          AdobeCoronarystentingis,bysomemeasures,themostoverusedprocedureinhospitals.Theproblemcoststhehealths